AnteoTech (ASX:ADO) share price soars 7% on news of rapid COVID-19 test

Shares in the biotech company are gaining today following an update on its rapid diagnostic test

| More on:
Group of Imugene scientists cheering in the lab after the company received another patent for HER-Vaxx

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The AnteoTech Ltd (ASX: ADO) share price is rocketing today. This comes after news the company has submitted its SARS-CoV-2 antigen rapid diagnostic test for Therapeutic Goods Administration (TGA) approval.

According to the company, its rapid diagnostic test is able to detect COVID-19 in 97.3% of cases and can provide results in 1 minute.  

At the time of writing, the AnteoTech share price is 29.5 cents, 7.27% higher than its previous close.

Let's take a closer look at today's news from the biotechnology company.

Rapid COVID-19 test submitted for TGA approval

The AnteoTech share price is soaring after the company announced it has submitted its COVID-19 rapid diagnostic test for TGA approval.

AnteoTech's test uses a nasal swap to test for COVID-19 infections in 1 minute. AnteoTech is also working on creating a saliva-based sampling method.

The test has been submitted for TGA approval alongside AnteoTech's Eugeni Reader Platform – a transportable device needed to read AnteoTech's rapid COVID-19 tests.

If the products receive TGA approval, AnteoTech will begin marketing, selling, and using the tests in Australia.

AnteoTech is already working with Australian distributor, Abacus dx, in the hope the rapid testing products will be approved.

Abacus has a strong pipeline of potential customers for the test across the healthcare and screening markets. AnteoTech believes the test's first sales will happen shortly after it's listed on the Australian Register of Therapeutic Goods.

The AnteoTech share price soared 14% last week when the company announced a distribution agreement to sell the rapid tests in Greece and Cyprus.

Additionally, if the TGA grants approval for the rapid test, it will create a benchmark for its efficacy and quality.

Currently, numerous COVID-19 rapid diagnostic tests are approved for use in Australia.

However, the TGA advises rapid diagnostic tests for COVID-19 shouldn't be relied upon. The body says the prevalence of COVID-19 in Australia is lower than the number of false positives or false negatives that would likely result from rapid testing.

AnteoTech share price snapshot

Today's gains included, the AnteoTech share price is 168% higher than it was at the start of 2021.

It has also gained 268% since this time last year.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Two doctors give the thumbs up to an x-ray
Healthcare Shares

One likely reason the market has soured on Pro Medicus

Is there opportunity for brave investors?

Read more »

Three health professionals at a hospital smile for the camera.
Healthcare Shares

Hedge the rise in your health insurance premium with these 2 ASX stocks

Sick of price rises? Get on the other side of the transaction.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

2 ASX 200 biotech stocks announcing big news today

Let's see how the market has responded to these announcements.

Read more »

Happy man holding Australian dollar notes, representing dividends.
Healthcare Shares

This ASX 200 stock is rocketing 17% after announcing a $300m special dividend

A huge dividend is expected to be paid to investors in the near future.

Read more »

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Healthcare Shares

CSL shares haven't been this cheap in 9 years: Time to buy?

Analysts think big returns could be on offer from this biotech giant.

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

Bell Potter names the best ASX healthcare stocks to buy now

The broker has good things to say about these stocks.

Read more »

Five healthcare workers standing together and smiling.
Healthcare Shares

Two ASX healthcare companies that are using AI to leverage their business

Interested in adding healthcare stocks integrating artificial intelligence to your portfolio? Here are two to consider. 

Read more »

Medical workers examine an xray or scan in a hospital laboratory.
Healthcare Shares

Pro Medicus shares up 255% in 2 years! Will the bubble burst?

Did you miss out or is it time to hop on board this runaway train?

Read more »